Science 37, the leader in expanding patient access to clinical trials, and Catalent®, a global leader in enabling pharma, biotech, and consumer healt...
Pre-submission file completed with French regulatory agency (ANSM) to discuss clinical trial protocol Phase IIa clinical trial planned to start in 202...
Kexing Biopharm (688136.SH) has officially entered into a comprehensive strategic partnership with IQVIA(NYSE:IQV), a global leader in clinica...
WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significan...
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, announced Novasign and Repligen have entered ...
WuXi XDC Cayman Inc., a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announ...
As regulatory uncertainty grows in the United States, US biotechs are increasingly looking to Australia as a stable and predictable launchpad for early-p...
BD a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral...
MaxisIT, a long-recognized provider of clinical data analytics platform for clinical trials, today announced its transformation into Maxis AI. This strat...
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corp...
INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment t...
NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company th...
Croda is pleased to announce the appointments of Stephen Oxley as Chief Financial Officer (CFO) and Executive Director, and Dr. Thomas Riermeier as Presi...
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025 Revenue grew 9.6% YoY to RMB 18,675.4 million, with ...
© 2025 Biopharma Boardroom. All Rights Reserved.
